Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy
- 13 April 2006
- journal article
- research article
- Published by Springer Science and Business Media LLC in International Journal Of Impotence Research
- Vol. 18 (5), 494-498
- https://doi.org/10.1038/sj.ijir.3901471
Abstract
Sex steroids are known to modulate serum lipoproteins. Studies have suggested that serum testosterone levels are associated with a beneficial lipid profile. Androgen deprivation therapy (ADT) is employed in the treatment of recurrent and metastatic prostate cancer (PCa), resulting in profound hypogonadism. As male hypogonadism unfavorably influences lipid profile and men with PCa have high cardiovascular mortality, we evaluated the effects of long-term ADT on fasting lipids. This Cross-sectional study was conducted in a university-based research institution. We evaluated 44 men, 16 undergoing ADT for at least 12 months before the study (ADT group), 14 age-matched eugonadal men with non-metastatic PCa who were status post prostatectomy and/or radiotherapy and not on ADT (non-ADT group) and 14 age-matched eugonadal controls (Control group). None of the men had known history of diabetes or dyslipidemia. Mean age was similar in the three groups (P=0.37). Serum total (PPPP=0.03). After adjustment for BMI, men on ADT continued to have significantly higher fasting levels of total cholesterol (P=0.02), LDL cholesterol (P=0.04) and non-HDL cholesterol (P=0.03) compared to the control group. No significant differences were seen in the levels of other lipoproteins between the three groups. These data show that men undergoing long-term ADT have higher total and LDL cholesterol than age-matched controls. Long-term prospective studies are needed to determine the time of onset of changes in these lipoproteins while on ADT and the influence of these changes on cardiovascular mortality.Keywords
This publication has 14 references indexed in Scilit:
- The Influence of Androgen Deprivation Therapy on Metabolism in Patients with Prostate CancerJournal of Clinical Endocrinology & Metabolism, 2005
- Effects of androgen substitution on lipid profile in the adult and aging hypogonadal maleActa Endocrinologica, 2004
- The Effect of Testosterone Replacement on Endogenous Inflammatory Cytokines and Lipid Profiles in Hypogonadal MenJournal of Clinical Endocrinology & Metabolism, 2004
- CHANGING PATTERNS IN COMPETING CAUSES OF DEATH IN MEN WITH PROSTATE CANCER: A POPULATION BASED STUDYJournal of Urology, 2004
- Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemiaClinical Science, 2003
- Changes in Body Composition during Androgen Deprivation Therapy for Prostate CancerJournal of Clinical Endocrinology & Metabolism, 2002
- The Effects of Induced Hypogonadism on Arterial Stiffness, Body Composition, and Metabolic Parameters in Males with Prostate CancerJournal of Clinical Endocrinology & Metabolism, 2001
- The association of hypotestosteronemia with coronary artery disease in men.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1994
- High-density lipoprotein cholesterol is not decreased if an aromatizable androgen is administeredMetabolism, 1990
- HYPOCHOLESTEROLAEMIA AND INCREASED ELIMINATION OF LOW-DENSITY LIPOPROTEINS IN METASTATIC CANCER OF THE PROSTATEThe Lancet, 1989